#2-56E. Stratifying Cancer Risk in Systemic Sclerosis: The Role of Autoantibodies (AR, 2025)

Systemic sclerosis (SSc) physicians must actively manage the well-established, yet often non-specific, risk of malignancy in their patients. This large multicenter cohort study, utilizing electronic health records from over 66,000 SSc patients, analyzed five-year incidences of hematologic and solid-organ cancers compared to matched controls. The research confirmed an overall elevated risk of all-type cancer (HR 1.17) in SSc patients, with notably high risks for esophageal cancer (HR 3.96), lung cancer (HR 2.32), and multiple myeloma (HR 2.13). The key finding is that cancer risk profiles vary significantly based on specific autoantibody status (anti-Scl-70, RNA polymerase III, or anticentromere). For instance, anti-Scl-70 positivity was linked to the most extensive profile, including hematologic and lung cancers. This knowledge enables personalized risk assessment. However, a critical caveat is the reliance on incomplete autoantibody data in the study population, which may limit the generalizability of these subgroup findings. This provides crucial real-world evidence for physicians, underscoring the need for heightened clinical awareness and potentially more targeted cancer surveillance strategies tailored to the patient's serologic profile.

Citation: Mahajan A., Vazquez-Machado M., Zangenah N., Sparks J.A., LaChance A.H. Distinct Cancer Risk Profiles in Patients With Systemic Sclerosis With Autoantibody Stratification. Arthritis & Rheumatology. 2025. DOI: 10.1002/art.43339

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.